Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging agents and regimens for multiple myeloma
Yang Yang, Yi Li, Huiyao Gu, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Tian Zheng, Ming Liu, Ya Zhang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 190
Targeting macrophages in hematological malignancies: recent advances and future directions
Wei Li, Fang Wang, Rongqun Guo, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 96
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
Global, regional, and national burden and quality of care of multiple myeloma, 1990–2019
Jiawei Geng, Jianhui Zhao, Rong Fan, et al.
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 8
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 46
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Zhaoyun Liu, Xintong Xu, Hui Liu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
Jianwei Qu, Yifan Hou, Qingxiao Chen, et al.
Oncogene (2021) Vol. 41, Iss. 3, pp. 400-413
Open Access | Times Cited: 33
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
José‐Ángel Hernández‐Rivas, Rafael Ríos, Cristina Encinas, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 27
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma
Daniel A. Ang, Jean-Michel Carter, Kamalakshi Deka, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review)
Y J Wang, Chao-Wei Zhang, Yulong Gao, et al.
Technology in Cancer Research & Treatment (2025) Vol. 24
Open Access
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review
Shaji Kumar, Xavier Leleu, Katja Weisel, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma
Yue Zhang, Xin Wang, Hongmei Luo, et al.
Biochemical Pharmacology (2025), pp. 116948-116948
Closed Access
Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy
Wenjing Xiao, Qiaodan Zhou, Xudong Wen, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 29
Genome Instability in Multiple Myeloma: Facts and Factors
Anna Y. Aksenova, Anna S. Zhuk, Artem G. Lada, et al.
Cancers (2021) Vol. 13, Iss. 23, pp. 5949-5949
Open Access | Times Cited: 28
Overcoming proteasome inhibitor resistance in the immunotherapy era
Bonell Patiño-Escobar, Alexis Talbot, Arun P. Wiita
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 8, pp. 507-518
Open Access | Times Cited: 12
Immunotherapy approaches for hematological cancers
Olivia L. Lanier, Edgar Pérez‐Herrero, Abielle P. D.’ Andrea, et al.
iScience (2022) Vol. 25, Iss. 11, pp. 105326-105326
Open Access | Times Cited: 18
Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China
Weijia Wu, Shuyi Ding, Mingming Zhang, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 701-709
Open Access | Times Cited: 9
Minimal residual disease in multiple myeloma: current status
Hong Ding, Juan Xu, Zhimei Lin, et al.
Biomarker Research (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 22
The present roles and future perspectives of Interleukin-6 in biliary tract cancer
Meng Zhou, Ruisi Na, Shihui Lai, et al.
Cytokine (2023) Vol. 169, pp. 156271-156271
Closed Access | Times Cited: 8
Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting
Ruogu Qi, Shanshan Wang, Jiayi Yu, et al.
Engineering (2024) Vol. 36, pp. 178-192
Open Access | Times Cited: 2
Treatment of multiple myeloma: What is the impact on T-cell function?
Chenggong Li, Xindi Wang, Jia Xu, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 2
Targeted Delivery Strategies for Multiple Myeloma and Their Adverse Drug Reactions
Shuting Li, Hongjie Wang, Shijun Xiong, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 832-832
Open Access | Times Cited: 2
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
Mengying Ke, Liqing Kang, Ling Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma
Qiuyun Jiang, Hongwu Mao, Guisong He, et al.
Cancer Letters (2022) Vol. 543, pp. 215791-215791
Closed Access | Times Cited: 10
Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
Hua Zhang, Jintong Chen, Mingyue Zhang, et al.
Medical Oncology (2022) Vol. 39, Iss. 5
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top